Dextroamphetamine Study Should Avoid Prior Stimulant Use, Pediatric Cmte. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA committee accepts recommendation from its Pediatric Ethics Subcommittee to allow a study of dextroamphetamine in healthy children to proceed. Stimulants should not be provided to participants prior to enrollment, committee says.
You may also be interested in...
Attention Deficit Study In Healthy Children Can Proceed Under Certain Conditions, Cmte. Says
NIH proposal to administer dextroamphetamine to healthy children represents only a slightly greater than minimal risk to study participants, FDA's Pediatric Ethics Subcommittee says. The Pediatric Advisory Committee will review the recommendations Sept. 15.
U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.
Sanofi-Aventis' Once-Daily Allegra-D To Launch Mid-Year
With the exception of Allegra, the company's "top 15" products produced double-digit sales growth in 2004. The fastest growing products include the long-acting insulin Lantus (up 80%), the osteoporosis agent Actonel (up 60%) and the oncologic Eloxatin (up 57%).